OpenURL Connection Search

Select item for more details and to access through your institution.

Second primary malignancy after multiple myeloma‐population trends and cause‐specific mortality.
Published in:
British Journal of Haematology, 2018, v. 182, n. 4, p. 513, doi. 10.1111/bjh.15426
By:
- Costa, Luciano J.;
- Godby, Kelly N.;
- Chhabra, Saurabh;
- Cornell, Robert Frank;
- Hari, Parameswaran;
- Bhatia, Smita
Publication type:
Article
A phase 1 clinical trial of oral eltanexor in patients with relapsed or refractory multiple myeloma.
Published in:
American Journal of Hematology, 2022, v. 97, n. 2, p. E54, doi. 10.1002/ajh.26420
By:
- Cornell, Robert Frank;
- Baz, Rachid;
- Richter, Joshua R.;
- Rossi, Adriana;
- Vogl, Dan T.;
- Chen, Christine;
- Shustik, Chaim;
- Alvarez, Mariano J.;
- Shen, Yao;
- Unger, T. J.;
- Ben‐Shahar, Osnat;
- Wang, Hongwei;
- Baloglu, Erkan;
- Senapedis, William;
- Ma, Xiwen;
- Landesman, Yosef;
- Bai, Xiang;
- Bader, Justin;
- Xu, Hongmei;
- Marshall, Tracey
Publication type:
Article
Phase 2b Results of the STORM Study: Oral Selinexor plus Low Dose Dexamethasone (Sd) in Patients with Penta-Refractory Myeloma (penta-MM).
Published in:
Clinical Lymphoma, Myeloma & Leukemia, 2018, v. 18, p. S249, doi. 10.1016/j.clml.2018.07.149
By:
- Jagannath, Sundar;
- Vogl, Dan T.;
- Dimopoulos, Meletios-Athanasios;
- Nooka, Ajay;
- Huff, Carol;
- Moreau, Philippe;
- Cole, Craig;
- Richter, Josh;
- Dingli, David;
- Vij, Ravi;
- Tuchman, Sascha;
- Raab, Marc-Steffen;
- Weisel, Katja;
- Delforge, Michel;
- Kaminetzky, David;
- Cornell, Robert Frank;
- Stewart, A. Keith;
- Hoffman, James;
- Godby, Kelly N.;
- Parker, Terri Lynn
Publication type:
Article
Apixaban for Primary Prevention of Venous Thromboembolism in Patients With Multiple Myeloma Receiving Immunomodulatory Therapy.
Published in:
Frontiers in Oncology, 2019, p. N.PAG, doi. 10.3389/fonc.2019.00045
By:
- Cornell, Robert Frank;
- Goldhaber, Samuel Z.;
- Engelhardt, Brian G.;
- Moslehi, Javid;
- Jagasia, Madan;
- Patton, Daryl;
- Harrell, Shelton;
- Hall, Robert;
- Wyatt, Houston;
- Piazza, Greg
Publication type:
Article
Weekly carfilzomib, lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: A phase 1b study.
Published in:
American Journal of Hematology, 2019, v. 94, n. 7, p. 794, doi. 10.1002/ajh.25498
By:
- Biran, Noa;
- Siegel, David;
- Berdeja, Jesus G.;
- Raje, Noopur;
- Cornell, Robert Frank;
- Alsina, Melissa;
- Kovacsovics, Tibor;
- Fang, Belle;
- Kimball, Amy S.;
- Landgren, Ola
Publication type:
Article
Chemotherapy-Induced Regression of an Adrenocorticotropin-Secreting Pituitary Carcinoma Accompanied by Secondary Adrenal Insufficiency.
Published in:
Case Reports in Endocrinology, 2013, p. 1, doi. 10.1155/2013/675298
By:
- Cornell, Robert Frank;
- Kelly, Daniel F.;
- Bordo, Gal;
- Carroll, Ty B.;
- Duong, Huy T.;
- Kim, Julie;
- Takasumi, Yuki;
- Thomas, James P.;
- Wong, Yee Lan;
- Findling, James W.
Publication type:
Article

Found: 6

Second primary malignancy after multiple myeloma‐population trends and cause‐specific mortality.

A phase 1 clinical trial of oral eltanexor in patients with relapsed or refractory multiple myeloma.

Phase 2b Results of the STORM Study: Oral Selinexor plus Low Dose Dexamethasone (Sd) in Patients with Penta-Refractory Myeloma (penta-MM).

Apixaban for Primary Prevention of Venous Thromboembolism in Patients With Multiple Myeloma Receiving Immunomodulatory Therapy.

Weekly carfilzomib, lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: A phase 1b study.

Chemotherapy-Induced Regression of an Adrenocorticotropin-Secreting Pituitary Carcinoma Accompanied by Secondary Adrenal Insufficiency.